<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>HIV-associated nephropathy (HIVAN)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">HIV-associated nephropathy (HIVAN)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">HIV-associated nephropathy (HIVAN)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christina M Wyatt, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Molly Fisher, DO, FASN</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul E Klotman, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alessia Fornoni, MD, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H11947711"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Human immunodeficiency virus (HIV) infection has been associated with both acute kidney injury (AKI) and chronic kidney disease (CKD). (See  <a class="medical medical_review" href="/z/d/html/14027.html" rel="external">"Overview of kidney disease in patients with HIV"</a>.)</p><p>HIV-associated nephropathy (HIVAN), the classic kidney disease associated with HIV infection, was first described in 1984 as a complication of AIDS [<a href="#rid1">1-3</a>] although HIVAN may also occur in patients with less advanced HIV infection or following acute seroconversion [<a href="#rid4">4,5</a>]. Histologically, HIVAN is a collapsing form of focal segmental glomerulosclerosis (FSGS) (<a class="graphic graphic_picture graphicRef90315" href="/z/d/graphic/90315.html" rel="external">picture 1</a>) accompanied by microcystic tubular dilatation and interstitial inflammation [<a href="#rid6">6</a>].</p><p>Issues related to HIVAN will be discussed in this topic. An overview of kidney disease in people with HIV and discussions of electrolyte abnormalities, dialysis, and transplantation in people with HIV are provided elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14027.html" rel="external">"Overview of kidney disease in patients with HIV"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2375.html" rel="external">"Electrolyte disturbances with HIV infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1915.html" rel="external">"Human immunodeficiency virus and dialysis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7332.html" rel="external">"Kidney transplantation in adults: Kidney transplantation in patients with HIV"</a>.)</p><p></p><p class="headingAnchor" id="H3466060613"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>HIVAN displays a striking racial predilection for individuals of African descent [<a href="#rid7">7</a>]. In studies of adult and pediatric people with HIV, 96 to 100 percent were of African descent [<a href="#rid8">8-11</a>]. According to data from the United States Renal Data System (USRDS), more than 85 percent of new end-stage kidney disease (ESKD) cases attributed to HIVAN occur in African Americans [<a href="#rid12">12</a>]. In individuals of African descent, the presence of <em>APOL1 </em>risk variants have been associated with a higher incidence of HIVAN [<a href="#rid13">13</a>]. (See <a class="local">'Pathogenesis'</a> below.)</p><p>The introduction of combination antiretroviral therapy (ART) substantially reduced the incidence of ESKD attributed to HIVAN [<a href="#rid12">12</a>]. In a large, urban cohort study, for example, the incidence of suspected or biopsy-proven HIVAN declined following the introduction of ART [<a href="#rid14">14</a>]. A large series of kidney biopsies in people with HIV between 1995 and 2004 demonstrated a decline in the proportion of biopsies revealing HIVAN from approximately 80 percent in 1997 to less than 30 percent in 2004 [<a href="#rid15">15</a>]. Data from the USRDS demonstrate a plateau in the annual incidence of ESKD attributed to HIVAN after 1995 [<a href="#rid12">12</a>]. Survival of patients with ESKD attributed to HIVAN has also improved although it remains lower than that of patients with ESKD from other causes [<a href="#rid12">12</a>].</p><p>Despite the decline in incidence of HIVAN and related ESKD among individuals treated with ART, HIVAN remains an important cause of kidney disease in people with HIV who are not taking ART due to nonadherence, intolerance, or previously undiagnosed HIV [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H1963448616"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of HIVAN is hypothesized to involve several factors:</p><p class="bulletIndent1"><span class="glyph">●</span>Infection of kidney epithelial cells by HIV and expression of HIV genes within infected kidney cells</p><p class="bulletIndent1"><span class="glyph">●</span>Host factors, including genetic susceptibility</p><p></p><p>Much of our current understanding of the pathogenesis of HIVAN has been derived from animal models, in particular the Tg26 HIV-1 transgenic mouse model [<a href="#rid17">17</a>]. This transgenic mouse model expresses a gag/pol-deleted HIV-1 provirus in the kidney and develops proteinuria, kidney failure, and histologic findings resembling human HIVAN [<a href="#rid17">17,18</a>]. Following the reciprocal transplantation of kidneys between transgenic and wild-type mice, kidney disease develops only in kidneys donated by transgenic animals, suggesting that HIV gene expression in kidney cells is required for the development of HIVAN [<a href="#rid19">19</a>]. Transgenic mouse models suggest that certain HIV genes, in particular <em>Nef</em> and <em>Vpr</em>, are specifically involved in the pathogenesis of HIVAN [<a href="#rid20">20-23</a>].</p><p>HIV directly infects glomerular and kidney tubular epithelial cells in humans with HIVAN [<a href="#rid24">24,25</a>]. In addition, in vitro experiments have shown that HIV transgene expression induces dedifferentiation and proliferation of glomerular epithelial cells and impairs cytokinesis in tubular epithelial cells.</p><p>The strong association between HIVAN and African ancestry indicates that host genetic factors are also important. Human genetic studies have identified single-nucleotide polymorphisms in the <em>APOL1</em> gene that are strongly linked to increased risk of HIVAN and non-HIVAN focal segmental glomerulosclerosis (FSGS) [<a href="#rid13">13,26-29</a>]. However, these variants, which are present almost exclusively in individuals of African descent but have been less commonly identified in other populations, are not required for the development of HIVAN and do not appear to be associated with the severity of disease among those with biopsy-proven HIVAN [<a href="#rid30">30</a>]. The mechanisms through which variants in <em>APOL1</em> promote HIVAN and other forms of FSGS have not been fully elucidated, although growing evidence suggests a gain-of-function effect of the risk variants. (See  <a class="medical medical_review" href="/z/d/html/117559.html" rel="external">"Focal segmental glomerulosclerosis: Genetic causes", section on 'FSGS in Black patients'</a> and  <a class="medical medical_review" href="/z/d/html/7236.html" rel="external">"Epidemiology of chronic kidney disease"</a>.) </p><p class="headingAnchor" id="H4120314614"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>HIVAN is characterized by the collapsing form of focal segmental glomerulosclerosis (FSGS) (<a class="graphic graphic_picture graphicRef90315" href="/z/d/graphic/90315.html" rel="external">picture 1</a>). (See  <a class="medical medical_review" href="/z/d/html/3049.html" rel="external">"Focal segmental glomerulosclerosis: Clinical features and diagnosis", section on 'Histologic variants'</a>.)</p><p>In addition to collapsing FSGS, HIVAN is typically characterized by dilated tubules and significant interstitial inflammation. Tubuloreticular inclusions may also be identified on electron microscopy (<a class="graphic graphic_picture graphicRef90316" href="/z/d/graphic/90316.html" rel="external">picture 2</a>) [<a href="#rid6">6,7</a>]. While this unique histologic pattern was initially considered pathognomonic for HIVAN, virtually indistinguishable findings have been reported in patients with systemic lupus erythematosus, patients treated with bisphosphonates and interferon, and patients with other viral infections, including SARS-CoV-2 infection. (See  <a class="medical medical_review" href="/z/d/html/3080.html" rel="external">"Collapsing focal segmental glomerulosclerosis (collapsing glomerulopathy)", section on 'Bisphosphonates and other drugs'</a> and  <a class="medical medical_review" href="/z/d/html/3080.html" rel="external">"Collapsing focal segmental glomerulosclerosis (collapsing glomerulopathy)", section on 'Infections'</a> and  <a class="medical medical_review" href="/z/d/html/127552.html" rel="external">"COVID-19: Issues related to acute kidney injury, glomerular disease, and hypertension"</a>.) </p><p>The glomerular lesion of HIVAN is also characterized by dedifferentiation and proliferation of glomerular epithelial cells, which are typically considered terminally differentiated cells, resulting in pseudocrescent formation [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H3500217794"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>In patients with classic HIVAN, the following features are usually present:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advanced HIV disease</strong> – Patients with HIVAN typically have a CD4 count less than 200 cells/microL. In a study of 57 patients with proven HIVAN, approximately one-half of whom were taking antiretroviral therapy (ART), the mean HIV viral load was greater than 30,000 copies/mL, and the mean CD4 cell count was 127 cells/microL (64 percent had a CD4 count less than 200 cells/microL) [<a href="#rid10">10</a>]. In two other studies, 81 and 90 percent of patients who presented with HIVAN had CD4 positive T cell counts less than 200 cells/microL [<a href="#rid8">8,9</a>]. In addition, HIVAN has been reported in patients with acute HIV infection [<a href="#rid4">4,5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nephrotic-range proteinuria</strong> – In a study of 71 children with HIVAN, 72 percent had nephrotic-range proteinuria at the time of presentation [<a href="#rid11">11</a>]. Studies in adults had similar findings [<a href="#rid8">8-10</a>]. Among 57 patients with HIVAN, for example, mean proteinuria was 4.1 g/day, and only 14 percent of patients had proteinuria less than 1.5 g/day [<a href="#rid10">10</a>]. However, patients with HIVAN may have substantially less proteinuria early during the course of their disease. As an example, a study from South Africa found early HIVAN in six of seven ART-naïve patients who had persistent moderately increased albuminuria (formerly called "microalbuminuria"); such patients would rarely undergo kidney biopsy in routine clinical practice [<a href="#rid32">32</a>]. These findings suggest that HIVAN should also be considered in patients with lesser degrees of proteinuria. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rapid decline in kidney function</strong> – At the time of HIVAN diagnosis, adult patients often have severely reduced kidney function, which is attributed to the rapidly progressive course. In two studies of adults with HIVAN, the mean estimated glomerular filtration rates (eGFR) at the time of HIVAN diagnosis were 10 and 20 mL/min per 1.73 m<sup>2</sup> [<a href="#rid9">9,10</a>]. Children may not have similarly severe kidney dysfunction at the time of presentation, although this may be a result of ascertainment bias rather than a true difference in the disease course. Among 71 South African children diagnosed with HIVAN, for example, only one-third had an eGFR less than 60 mL/min per 1.73 m<sup>2</sup> [<a href="#rid11">11</a>].</p><p></p><p>Other manifestations, such as hematuria, hypertension, and edema, may also be present although the frequencies of hypertension and edema are lower than may be expected in patients with severe proteinuria and decreased eGFR. In three studies of adult and pediatric patients with HIVAN, the following characteristics were observed [<a href="#rid9">9-11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hematuria – 45 to 75 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension – 12 to 26 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Edema – 22 to 59 percent</p><p></p><p>In addition, the presence of enlarged, hyperechogenic kidneys on ultrasonography has been reported in more than 50 percent of patients with HIVAN [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H565760997"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H832806396"><span class="h2">When to suspect HIVAN</span><span class="headingEndMark"> — </span>The diagnosis of HIVAN should be suspected in any patient with HIV who presents with nephrotic-range proteinuria and rapidly declining kidney function, even in the absence of edema. Our suspicion is particularly high if the patient has a CD4 cell count &lt;200 cells/microL, HIV viremia, and/or has a history of nonadherence to antiretroviral therapy (ART). HIVAN should also be considered in patients with milder proteinuria; however, other causes (eg, medication toxicity) may be more likely. (See <a class="local">'Clinical manifestations'</a> above.)</p><p class="headingAnchor" id="H8499406"><span class="h2">Establishing the diagnosis</span><span class="headingEndMark"> — </span>Kidney biopsy is currently the only way to establish a definitive diagnosis of HIVAN as patients suspected of having HIVAN on clinical grounds often have an alternative histologic diagnosis [<a href="#rid34">34</a>]. There are no specific laboratory findings that can be used to distinguish HIVAN from other forms of glomerular disease, including other forms of HIV-associated kidney disease. If a kidney biopsy cannot be performed safely, we manage patients with suspected HIVAN similarly as those with biopsy-proven HIVAN. (See <a class="local">'Pathology'</a> above and <a class="local">'Initial therapy'</a> below.) </p><p>As noted above, patients suspected of having HIVAN based on the clinical presentation may actually have a different histologic diagnosis. As an example, in a study of 107 African American people with HIV who had proteinuria greater than 3 g/day, kidney biopsy revealed the following [<a href="#rid35">35</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>HIVAN – 56 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Classic focal segmental glomerulosclerosis (FSGS) – 21 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Membranoproliferative glomerulonephritis – 6 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Amyloidosis – 4 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Diabetic kidney disease – 4 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Lupus-like immune complex glomerulonephritis – 4 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Other – 5 percent</p><p></p><p>In a series of 152 kidney biopsies performed in adults with HIV at the same urban center between 1995 and 2004, the proportion of kidney biopsies demonstrating HIVAN declined over time [<a href="#rid15">15</a>]. Overall, HIVAN accounted for only 35 percent of biopsies; other common diagnoses included noncollapsing FSGS (22 percent of biopsies) and a variety of immune complex glomerular diseases. In an updated biopsy series from the same center, both HIVAN and immune complex kidney diseases occurred predominantly in African Americans with advanced HIV disease [<a href="#rid36">36</a>], and the addition of <em>APOL1</em> genotype to clinical data did not significantly improve the prediction of HIVAN [<a href="#rid37">37</a>]. In a more contemporary series of 437 kidney biopsies interpreted at a single center between 2010 and 2018, HIVAN remained the third most common biopsy diagnosis in people with HIV and the most common finding among those not taking ART [<a href="#rid16">16</a>].</p><p>These and other studies illustrate the importance of obtaining a kidney biopsy to confirm a suspected diagnosis of HIVAN and exclude alternative diagnoses. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H1930225778"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis in people with HIV who present with proteinuria and decreased glomerular filtration rate (GFR) includes HIVAN and also the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Noncollapsing focal segmental glomerulosclerosis (FSGS) – In the modern era of antiretroviral therapy (ART), there has been a shift away from the classic presentation of HIVAN to a more indolent presentation of slowly progressive kidney disease. Histologically, this is characterized as noncollapsing FSGS and is more often observed in people with HIV receiving ART, who generally have CD4 cell counts &gt;200 cells/microL and who have undetectable viral loads. To distinguish this form of noncollapsing FSGS from classic HIVAN, the Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference classified this entity as FSGS (not otherwise specified) in the setting of HIV [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1">The roles of HIV infection and ART in the pathogenesis and treatment, respectively, of noncollapsing FSGS are not known. Case series of kidney biopsies performed after widespread use of ART demonstrate a decrease in the prevalence of HIVAN and a simultaneous increase in the prevalence of noncollapsing FSGS. These data suggest that noncollapsing FSGS is a milder form of HIVAN that is partially treated with ART although this has not been proven [<a href="#rid9">9,15</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immune complex-mediated glomerulonephritis, including immunoglobulin A (IgA) nephropathy, membranous nephropathy, membranoproliferative glomerulonephritis, and a "lupus-like" proliferative glomerulonephritis. (See  <a class="medical medical_review" href="/z/d/html/14027.html" rel="external">"Overview of kidney disease in patients with HIV", section on 'Immune complex kidney disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glomerulonephritis due to coinfection with hepatitis C or hepatitis B virus. (See  <a class="medical medical_review" href="/z/d/html/14027.html" rel="external">"Overview of kidney disease in patients with HIV", section on 'Glomerulonephritis due to hepatitis C virus coinfection'</a> and  <a class="medical medical_review" href="/z/d/html/3119.html" rel="external">"Kidney disease associated with hepatitis B virus infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetic kidney disease, amyloidosis, or other noninfectious glomerulopathies – With the aging of the patient population with HIV, comorbid kidney disease due to traditional chronic kidney disease (CKD) risk factors is increasingly important. (See  <a class="medical medical_review" href="/z/d/html/14027.html" rel="external">"Overview of kidney disease in patients with HIV"</a>.)</p><p></p><p class="headingAnchor" id="H1657574601"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Treatments that have been examined for patients with HIVAN include antiretroviral therapy (ART); renin-angiotensin system inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs); and glucocorticoids. None of these therapies have been evaluated in randomized clinical trials. Our approach to the treatment of HIVAN is presented below.</p><p class="headingAnchor" id="H3366932344"><span class="h2">Initial therapy</span></p><p class="headingAnchor" id="H3021879218"><span class="h3">Antiretroviral therapy for all patients</span><span class="headingEndMark"> — </span>All patients with HIV infection should receive ART, regardless of CD4 count. (See  <a class="medical medical_review" href="/z/d/html/3777.html" rel="external">"When to initiate antiretroviral therapy in persons with HIV", section on 'Universal treatment'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with HIVAN who are not already receiving ART, ART should be initiated as soon as possible. The selection of ART regimen, particularly in the setting of impaired kidney function, is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/129782.html" rel="external">"Selecting antiretroviral regimens for treatment-naive persons with HIV-1: Patients with comorbid conditions", section on 'Reduced kidney function'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with HIVAN who are already receiving ART, medication adherence should be assessed. Those who are adherent to ART but have a detectable viral load should be evaluated for drug resistance mutations to determine if their ART regimen should be changed. (See  <a class="medical medical_review" href="/z/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy"</a>.) </p><p></p><p class="bulletIndent1">In all patients, the ART regimen may need to be adjusted for estimated glomerular filtration rate (eGFR). (See  <a class="medical medical_review" href="/z/d/html/3766.html" rel="external">"Switching antiretroviral therapy for adults with HIV-1 and a suppressed viral load"</a>.)</p><p></p><p>No randomized trials have specifically examined the effect of ART in patients with HIVAN [<a href="#rid39">39</a>]. Evidence suggesting benefit from ART in HIVAN comes primarily from observational studies [<a href="#rid36">36,40-42</a>] and case reports of kidney function recovery after initiation of ART [<a href="#rid43">43,44</a>]. In addition, data from the United States Renal Data System (USRDS) suggest a benefit of ART on the epidemiology of end-stage kidney disease (ESKD) attributed to HIVAN.</p><p>As an example, the association of ART initiation with kidney disease outcomes was analyzed in a retrospective cohort of 36 patients with biopsy-proven HIVAN who did not require dialysis at the time of kidney biopsy; 26 were treated with ART, and 10 received no ART [<a href="#rid41">41</a>]. Kidney disease outcomes were significantly better among patients treated with ART:</p><p class="bulletIndent1"><span class="glyph">●</span>Median kidney survival was substantially longer among those receiving ART (18.4 versus 3.9 months). However, the mean serum creatinine at baseline was lower in patients who received ART (4.7 versus 7.8 mg/dL), and the results were not adjusted for baseline kidney function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients treated with ART within three months of biopsy, the risk of needing dialysis was lower if a complete virologic response was achieved although this was not significant.</p><p></p><p>Other retrospective biopsy series have also demonstrated improved kidney disease outcomes with ART among patients with HIVAN [<a href="#rid36">36,40</a>].</p><p class="headingAnchor" id="H2737510473"><span class="h3">Additional therapies for proteinuria or hypertension</span></p><p class="headingAnchor" id="H2852745354"><span class="h4">ACE inhibitors or ARBs</span><span class="headingEndMark"> — </span>Patients with HIVAN who have proteinuria and/or hypertension should be treated with an ACE inhibitor or ARB. This approach is similar to that for patients with proteinuric chronic kidney disease (CKD), as discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Effect of renin-angiotensin system inhibitors on progression of CKD'</a> and  <a class="medical medical_review" href="/z/d/html/3872.html" rel="external">"Overview of hypertension in acute and chronic kidney disease", section on 'Choice of antihypertensive therapy'</a>.) </p><p>The efficacy and safety of ACE inhibitors and ARBs have been extrapolated from rigorous studies in other glomerular diseases and from observational studies in patients with HIVAN [<a href="#rid40">40,45-47</a>]. There are <strong>no</strong> randomized trials of renin-angiotensin system inhibitors for the treatment of HIVAN.</p><p>The following examples illustrate the range of findings in support of treating patients who have HIVAN with ACE inhibitors or ARBs:</p><p class="bulletIndent1"><span class="glyph">●</span>A short-term study of 11 non-nephrotic and 9 nephrotic patients with biopsy-proven HIVAN reported more favorable changes in serum creatinine and 24-hour urine protein excretion among patients treated with <a class="drug drug_general" data-topicid="8479" href="/z/d/drug information/8479.html" rel="external">fosinopril</a> (10 mg/day) as compared with untreated patients [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent study demonstrated significantly longer kidney survival for patients treated with <a class="drug drug_general" data-topicid="8479" href="/z/d/drug information/8479.html" rel="external">fosinopril</a> as compared with untreated patients, despite similar characteristics and kidney function at baseline (median kidney survival of 480 days for treated patients versus 146 days for untreated patients) [<a href="#rid46">46</a>].</p><p></p><p>In the absence of data to guide dosing, it is reasonable to adopt the goals for blood pressure and proteinuria control used in other nondiabetic chronic kidney diseases (CKD). (See  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a>.)</p><p class="headingAnchor" id="H2915953960"><span class="h4">SGLT2 inhibitors</span><span class="headingEndMark"> — </span>As with other patients with proteinuric CKD, patients with HIVAN who have persistent proteinuria in spite of treatment with an ACE inhibitor or ARB may benefit from addition of a sodium-glucose cotransporter 2 (SGLT2) inhibitor. (See  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Patients with proteinuria'</a>.)</p><p>There are currently no data on the efficacy and safety of SGLT2 inhibitors for the treatment of HIVAN. However, data from large randomized trials have demonstrated that SGLT2 inhibitors slow progression of nondiabetic proteinuric CKD, including focal segmental glomerulosclerosis (FSGS) [<a href="#rid48">48,49</a>]. These studies are presented in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Patients with proteinuria'</a>.)</p><p class="headingAnchor" id="H2126958489"><span class="h3">No role for routine glucocorticoids</span><span class="headingEndMark"> — </span>There is generally no role for routine glucocorticoids in patients with HIVAN. Although small observational studies have suggested that glucocorticoid therapy may improve kidney function and reduce proteinuria in patients with HIVAN [<a href="#rid50">50,51</a>], these studies were conducted before or early after the introduction of effective ART, and adverse events were common. In patients whose kidney function is not improving with therapy, the use of glucocorticoids may be considered on a case-by-case basis, weighing the risks of infection and metabolic derangements against the risk of kidney disease progression.</p><p class="headingAnchor" id="H2598893059"><span class="h2">Monitoring response to therapy</span><span class="headingEndMark"> — </span>All patients with HIVAN should be monitored during therapy to evaluate treatment response. We assess the serum creatinine level, eGFR, and urine protein excretion (by spot urine protein-to-creatinine ratio or spot urine albumin-to-creatinine ratio), with the frequency of assessments guided by the severity of the clinical presentation. In addition, we routinely monitor the patient's HIV viral RNA level and CD4 cell count. (See  <a class="medical medical_review" href="/z/d/html/3770.html" rel="external">"Patient monitoring during HIV antiretroviral therapy"</a>.)</p><p>Patients with HIVAN should have routine monitoring and care, including management of complications of CKD and timely preparation for dialysis or transplantation, similar to patients with CKD who do not have HIV. The general care of such patients is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults"</a>.)</p><p class="headingAnchor" id="H4239415236"><span class="h2">Dialysis and transplantation</span><span class="headingEndMark"> — </span>Despite treatment with ART and adjunctive therapies such as renin-angiotensin inhibitors and SGLT2 inhibitors, some patients with HIVAN will progress to ESKD and require kidney replacement therapy with dialysis and/or kidney transplantation. (See <a class="local">'Prognosis'</a> below.)</p><p>Survival rates of people with HIV on dialysis have improved substantially with the introduction of effective ART, but mortality remains higher than among patients on dialysis without HIV [<a href="#rid52">52</a>]. There is no evidence favoring one dialysis modality over another. Specific issues related to HIV infection in patients on dialysis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1915.html" rel="external">"Human immunodeficiency virus and dialysis"</a>.)</p><p>Transplantation is a viable option for patients with HIVAN and ESKD; however, there is a risk of HIVAN recurrence in the allograft. Kidney transplantation in people with HIV, including the use of HIV-positive donor organs, is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7332.html" rel="external">"Kidney transplantation in adults: Kidney transplantation in patients with HIV"</a>.)</p><p class="headingAnchor" id="H3761233907"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The prognosis in patients with HIVAN is poor, even among those treated with antiretroviral therapy (ART). Many such patients will develop end-stage kidney disease (ESKD). The following examples illustrate the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>A French study examined the outcomes of 57 patients diagnosed with HIVAN, one-half of whom were already taking ART at the time of diagnosis [<a href="#rid10">10</a>]. The other one-half initiated ART within one month of the diagnosis of HIVAN. Most patients were also treated with inhibitors of the renin-angiotensin system. A total of 51 patients were followed for a median of approximately two years. During that time, 6 patients died and 30 developed ESKD (71 percent of those followed had one of these two outcomes). Patients who were already taking ART at the time of HIVAN diagnosis were more likely to develop ESKD, as were those who developed HIVAN despite complete virologic suppression.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A British study followed 31 patients with biopsy-proven HIVAN for a median of four and a half years; ART was initiated in 29 of the 31 patients within one month of HIVAN diagnosis [<a href="#rid53">53</a>]. ESKD developed in 15 of these 31 patients (48 percent). Virologic suppression was achieved in approximately 70 percent of patients, with no difference among patients who did and did not subsequently develop ESKD.</p><p></p><p class="headingAnchor" id="H1292174141"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110250.html" rel="external">"Society guideline links: Glomerular disease in adults"</a>.)</p><p class="headingAnchor" id="H5579022"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– HIV-associated nephropathy (HIVAN), the classic kidney disease associated with HIV infection, is a collapsing form of focal segmental glomerulosclerosis (FSGS) accompanied by microcystic tubular dilatation and interstitial inflammation. (See <a class="local">'Introduction'</a> above and <a class="local">'Pathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– The pathogenesis of HIVAN is hypothesized to involve direct infection of kidney epithelial cells by HIV with subsequent expression of HIV genes in a genetically susceptible host. The strong associations of HIV with African ancestry and <em>APOL1</em> gene polymorphisms illustrate the importance of host genetic factors. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– HIVAN classically presents with heavy proteinuria and a rapid decline in kidney function in a person with advanced HIV disease. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis of HIVAN should be suspected in any patient with HIV who presents with nephrotic-range proteinuria and rapidly declining kidney function. Our suspicion is particularly high if the patient has a CD4 cell count &lt;200 cells/microL, HIV viremia, and/or has a history of nonadherence to antiretroviral therapy (ART). Kidney biopsy is currently the only way to establish a definitive diagnosis of HIVAN. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– Our approach to the treatment of HIVAN is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All patients with HIV infection should receive ART, regardless of CD4 count. For patients with HIVAN who are not already receiving ART, ART should be initiated as soon as possible. For patients who are already receiving ART, medication adherence should be assessed. (See <a class="local">'Antiretroviral therapy for all patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with HIVAN who have proteinuria and/or hypertension should be treated with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blockers (ARB). This approach is similar to that for patients with proteinuric chronic kidney disease (CKD). Patients who have persistent proteinuria in spite of treatment with an ACE inhibitor or ARB may benefit from addition of a sodium-glucose cotransporter 2 (SGLT2) inhibitor. (See <a class="local">'ACE inhibitors or ARBs'</a> above and <a class="local">'SGLT2 inhibitors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There is generally no role for routine glucocorticoids in patients with HIVAN. In patients whose kidney function is not improving with therapy, the use of glucocorticoids may be considered on a case-by-case basis, weighing the risks of infection and metabolic derangements against the risk of kidney disease progression. (See <a class="local">'No role for routine glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis </strong>– The prognosis in patients with HIVAN is poor, even among those treated with ART. Many such patients will develop end-stage kidney disease (ESKD). (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gardenswartz MH, Lerner CW, Seligson GR, et al. Renal disease in patients with AIDS: a clinicopathologic study. Clin Nephrol 1984; 21:197.</a></li><li><a class="nounderline abstract_t">Pardo V, Aldana M, Colton RM, et al. Glomerular lesions in the acquired immunodeficiency syndrome. Ann Intern Med 1984; 101:429.</a></li><li><a class="nounderline abstract_t">Rao TK, Filippone EJ, Nicastri AD, et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 1984; 310:669.</a></li><li><a class="nounderline abstract_t">Winston JA, Bruggeman LA, Ross MD, et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 2001; 344:1979.</a></li><li><a class="nounderline abstract_t">Levin ML, Palella F, Shah S, et al. Hiv-associated nephropathy occurring before HIV antibody seroconversion. Am J Kidney Dis 2001; 37:E39.</a></li><li><a class="nounderline abstract_t">Laurinavicius A, Hurwitz S, Rennke HG. Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathological and follow-up study. Kidney Int 1999; 56:2203.</a></li><li><a class="nounderline abstract_t">Abbott KC, Hypolite I, Welch PG, Agodoa LY. Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era. J Nephrol 2001; 14:377.</a></li><li><a class="nounderline abstract_t">Williams DI, Williams DJ, Williams IG, et al. Presentation, pathology, and outcome of HIV associated renal disease in a specialist centre for HIV/AIDS. Sex Transm Infect 1998; 74:179.</a></li><li><a class="nounderline abstract_t">Lescure FX, Flateau C, Pacanowski J, et al. HIV-associated kidney glomerular diseases: changes with time and HAART. Nephrol Dial Transplant 2012; 27:2349.</a></li><li><a class="nounderline abstract_t">Bigé N, Lanternier F, Viard JP, et al. Presentation of HIV-associated nephropathy and outcome in HAART-treated patients. Nephrol Dial Transplant 2012; 27:1114.</a></li><li><a class="nounderline abstract_t">Ramsuran D, Bhimma R, Ramdial PK, et al. The spectrum of HIV-related nephropathy in children. Pediatr Nephrol 2012; 27:821.</a></li><li><a class="nounderline abstract_t">Razzak Chaudhary S, Workeneh BT, Montez-Rath ME, et al. Trends in the outcomes of end-stage renal disease secondary to human immunodeficiency virus-associated nephropathy. Nephrol Dial Transplant 2015; 30:1734.</a></li><li><a class="nounderline abstract_t">Papeta N, Kiryluk K, Patel A, et al. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol 2011; 22:1991.</a></li><li><a class="nounderline abstract_t">Lucas GM, Eustace JA, Sozio S, et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18:541.</a></li><li><a class="nounderline abstract_t">Berliner AR, Fine DM, Lucas GM, et al. Observations on a cohort of HIV-infected patients undergoing native renal biopsy. Am J Nephrol 2008; 28:478.</a></li><li><a class="nounderline abstract_t">Kudose S, Santoriello D, Bomback AS, et al. The spectrum of kidney biopsy findings in HIV-infected patients in the modern era. Kidney Int 2020; 97:1006.</a></li><li><a class="nounderline abstract_t">Dickie P, Felser J, Eckhaus M, et al. HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. Virology 1991; 185:109.</a></li><li><a class="nounderline abstract_t">Kopp JB, Klotman ME, Adler SH, et al. Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc Natl Acad Sci U S A 1992; 89:1577.</a></li><li><a class="nounderline abstract_t">Bruggeman LA, Dikman S, Meng C, et al. Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J Clin Invest 1997; 100:84.</a></li><li><a class="nounderline abstract_t">Dickie P, Roberts A, Uwiera R, et al. Focal glomerulosclerosis in proviral and c-fms transgenic mice links Vpr expression to HIV-associated nephropathy. Virology 2004; 322:69.</a></li><li><a class="nounderline abstract_t">Kajiyama W, Kopp JB, Marinos NJ, et al. Glomerulosclerosis and viral gene expression in HIV-transgenic mice: role of nef. Kidney Int 2000; 58:1148.</a></li><li><a class="nounderline abstract_t">Hanna Z, Kay DG, Rebai N, et al. Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 1998; 95:163.</a></li><li><a class="nounderline abstract_t">Husain M, Gusella GL, Klotman ME, et al. HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. J Am Soc Nephrol 2002; 13:1806.</a></li><li><a class="nounderline abstract_t">Bruggeman LA, Ross MD, Tanji N, et al. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 2000; 11:2079.</a></li><li><a class="nounderline abstract_t">Ross MJ, Bruggeman LA, Wilson PD, Klotman PE. Microcyst formation and HIV-1 gene expression occur in multiple nephron segments in HIV-associated nephropathy. J Am Soc Nephrol 2001; 12:2645.</a></li><li><a class="nounderline abstract_t">Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40:1175.</a></li><li><a class="nounderline abstract_t">Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329:841.</a></li><li><a class="nounderline abstract_t">Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011; 22:2129.</a></li><li><a class="nounderline abstract_t">Estrella MM, Wyatt CM, Pearce CL, et al. Host APOL1 genotype is independently associated with proteinuria in HIV infection. Kidney Int 2013; 84:834.</a></li><li><a class="nounderline abstract_t">Atta MG, Estrella MM, Kuperman M, et al. HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics. Kidney Int 2012; 82:338.</a></li><li><a class="nounderline abstract_t">Barisoni L, Kriz W, Mundel P, D'Agati V. The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 1999; 10:51.</a></li><li><a class="nounderline abstract_t">Han TM, Naicker S, Ramdial PK, Assounga AG. A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int 2006; 69:2243.</a></li><li><a class="nounderline abstract_t">Eze CU, Eze CU, Adeyomoye A. Sonographic evaluation of kidney echogenicity and morphology among HIV sero-positive adults at Lagos University Teaching Hospital. J Ultrasound 2018; 21:25.</a></li><li><a class="nounderline abstract_t">D'Agati V, Appel GB. Renal pathology of human immunodeficiency virus infection. Semin Nephrol 1998; 18:406.</a></li><li><a class="nounderline abstract_t">Atta MG, Choi MJ, Longenecker JC, et al. Nephrotic range proteinuria and CD4 count as noninvasive indicators of HIV-associated nephropathy. Am J Med 2005; 118:1288.</a></li><li><a class="nounderline abstract_t">Foy MC, Estrella MM, Lucas GM, et al. Comparison of risk factors and outcomes in HIV immune complex kidney disease and HIV-associated nephropathy. Clin J Am Soc Nephrol 2013; 8:1524.</a></li><li><a class="nounderline abstract_t">Atta MG, Estrella MM, Skorecki KL, et al. Association of APOL1 Genotype with Renal Histology among Black HIV-Positive Patients Undergoing Kidney Biopsy. Clin J Am Soc Nephrol 2016; 11:262.</a></li><li><a class="nounderline abstract_t">Swanepoel CR, Atta MG, D'Agati VD, et al. Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2018; 93:545.</a></li><li><a class="nounderline abstract_t">Yahaya I, Uthman OA, Uthman MM. Interventions for HIV-associated nephropathy. Cochrane Database Syst Rev 2013; :CD007183.</a></li><li><a class="nounderline abstract_t">Szczech LA, Gupta SK, Habash R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004; 66:1145.</a></li><li><a class="nounderline abstract_t">Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 2006; 21:2809.</a></li><li><a class="nounderline abstract_t">Cosgrove CJ, Abu-Alfa AK, Perazella MA. Observations on HIV-associated renal disease in the era of highly active antiretroviral therapy. Am J Med Sci 2002; 323:102.</a></li><li><a class="nounderline abstract_t">Kirchner JT. Resolution of renal failure after initiation of HAART: 3 cases and a discussion of the literature. AIDS Read 2002; 12:103.</a></li><li><a class="nounderline abstract_t">Scheurer D. Rapid reversal of renal failure after initiation of HAART: a case report. AIDS Read 2004; 14:443.</a></li><li><a class="nounderline abstract_t">Kimmel PL, Mishkin GJ, Umana WO. Captopril and renal survival in patients with human immunodeficiency virus nephropathy. Am J Kidney Dis 1996; 28:202.</a></li><li><a class="nounderline abstract_t">Wei A, Burns GC, Williams BA, et al. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int 2003; 64:1462.</a></li><li><a class="nounderline abstract_t">Burns GC, Paul SK, Toth IR, Sivak SL. Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy. J Am Soc Nephrol 1997; 8:1140.</a></li><li><a class="nounderline abstract_t">Wheeler DC, Jongs N, Stefansson BV, et al. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Nephrol Dial Transplant 2022; 37:1647.</a></li><li><a class="nounderline abstract_t">Wheeler DC, Toto RD, Stefánsson BV, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 2021; 100:215.</a></li><li><a class="nounderline abstract_t">Eustace JA, Nuermberger E, Choi M, et al. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int 2000; 58:1253.</a></li><li><a class="nounderline abstract_t">Smith MC, Austen JL, Carey JT, et al. Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Am J Med 1996; 101:41.</a></li><li><a class="nounderline abstract_t">Sawinski D, Forde KA, Locke JE, et al. Race but not Hepatitis C co-infection affects survival of HIV+ individuals on dialysis in contemporary practice. Kidney Int 2018; 93:706.</a></li><li><a class="nounderline abstract_t">Post FA, Campbell LJ, Hamzah L, et al. Predictors of renal outcome in HIV-associated nephropathy. Clin Infect Dis 2008; 46:1282.</a></li></ol></div><div id="topicVersionRevision">Topic 14026 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6733986" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Renal disease in patients with AIDS: a clinicopathologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6476632" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Glomerular lesions in the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6700641" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11430327" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11325704" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hiv-associated nephropathy occurring before HIV antibody seroconversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10594796" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathological and follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11730270" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9849552" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Presentation, pathology, and outcome of HIV associated renal disease in a specialist centre for HIV/AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22248510" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : HIV-associated kidney glomerular diseases: changes with time and HAART.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21745806" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Presentation of HIV-associated nephropathy and outcome in HAART-treated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22205506" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The spectrum of HIV-related nephropathy in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26175146" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Trends in the outcomes of end-stage renal disease secondary to human immunodeficiency virus-associated nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21997397" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15090808" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18176076" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Observations on a cohort of HIV-infected patients undergoing native renal biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32278618" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The spectrum of kidney biopsy findings in HIV-infected patients in the modern era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1926769" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : HIV-associated nephropathy in transgenic mice expressing HIV-1 genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1542649" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9202060" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15063118" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Focal glomerulosclerosis in proviral and c-fms transgenic mice links Vpr expression to HIV-associated nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10972678" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Glomerulosclerosis and viral gene expression in HIV-transgenic mice: role of nef.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9790524" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12089376" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11053484" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Renal epithelium is a previously unrecognized site of HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11729233" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Microcyst formation and HIV-1 gene expression occur in multiple nephron segments in HIV-associated nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18794856" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20647424" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Association of trypanolytic ApoL1 variants with kidney disease in African Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21997394" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23715117" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Host APOL1 genotype is independently associated with proteinuria in HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22495294" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9890309" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16672914" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29374399" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Sonographic evaluation of kidney echogenicity and morphology among HIV sero-positive adults at Lagos University Teaching Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9692353" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Renal pathology of human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16271919" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Nephrotic range proteinuria and CD4 count as noninvasive indicators of HIV-associated nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23685946" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Comparison of risk factors and outcomes in HIV immune complex kidney disease and HIV-associated nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26668025" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Association of APOL1 Genotype with Renal Histology among Black HIV-Positive Patients Undergoing Kidney Biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29398134" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23440812" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Interventions for HIV-associated nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15327410" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16864598" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Antiretroviral therapy in the treatment of HIV-associated nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11863077" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Observations on HIV-associated renal disease in the era of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11966239" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Resolution of renal failure after initiation of HAART: 3 cases and a discussion of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15338525" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Rapid reversal of renal failure after initiation of HAART: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8768914" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Captopril and renal survival in patients with human immunodeficiency virus nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12969167" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9219164" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34850160" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33878338" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10972688" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8686713" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29107361" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Race but not Hepatitis C co-infection affects survival of HIV+ individuals on dialysis in contemporary practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18444868" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Predictors of renal outcome in HIV-associated nephropathy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
